BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 12201054)

  • 1. Risk coefficient for gamma-rays with regard to solid cancer.
    Kellerer AM; Walsh L; Nekolla EA
    Radiat Environ Biophys; 2002 Jun; 41(2):113-23. PubMed ID: 12201054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer risk estimates for gamma-rays with regard to organ-specific doses. Part I: All solid cancers combined.
    Walsh L; Rühm W; Kellerer AM
    Radiat Environ Biophys; 2004 Sep; 43(3):145-51. PubMed ID: 15309386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutron versus gamma-ray risk estimates. Inferences from the cancer incidence and mortality data in Hiroshima.
    Kellerer AM; Nekolla E
    Radiat Environ Biophys; 1997 Jun; 36(2):73-83. PubMed ID: 9271794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of possible modifications to the DS86 dosimetry on neutron risk and relative biological effectiveness.
    Hunter N; Charles MW
    J Radiol Prot; 2002 Dec; 22(4):357-70. PubMed ID: 12546224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutron relative biological effectiveness for solid cancer incidence in the Japanese A-bomb survivors: an analysis considering the degree of independent effects from γ-ray and neutron absorbed doses with hierarchical partitioning.
    Walsh L
    Radiat Environ Biophys; 2013 Mar; 52(1):29-36. PubMed ID: 23161400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer risk estimates for gamma-rays with regard to organ-specific doses Part II: site-specific solid cancers.
    Walsh L; Rühm W; Kellerer AM
    Radiat Environ Biophys; 2004 Dec; 43(4):225-31. PubMed ID: 15645312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indications of the neutron effect contribution in the solid cancer data of the A-bomb survivors.
    Kellerer AM; Rühm W; Walsh L
    Health Phys; 2006 Jun; 90(6):554-64. PubMed ID: 16691103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solid cancer risk coefficient for fast neutrons in terms of effective dose.
    Kellerer AM; Walsh L
    Radiat Res; 2002 Jul; 158(1):61-8. PubMed ID: 12071804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk estimation for fast neutrons with regard to solid cancer.
    Kellerer AM; Walsh L
    Radiat Res; 2001 Dec; 156(6):708-17. PubMed ID: 11741494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the Relative Biological Effectiveness of Neutrons across Organs of Varying Depth among the Atomic Bomb Survivors.
    Cordova KA; Cullings HM
    Radiat Res; 2019 Aug; 192(4):380-387. PubMed ID: 31390313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer risk estimates from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy.
    Schneider U; Walsh L
    Radiat Environ Biophys; 2008 Apr; 47(2):253-63. PubMed ID: 18157543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer incidence risks above and below 1 Gy for radiation protection in space.
    Hafner L; Walsh L; Schneider U
    Life Sci Space Res (Amst); 2021 Feb; 28():41-56. PubMed ID: 33612179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accounting for neutron exposure in the Japanese atomic bomb survivors.
    Cullings HM; Pierce DA; Kellerer AM
    Radiat Res; 2014 Dec; 182(6):587-98. PubMed ID: 25409123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung cancer risk in mice: analysis of fractionation effects and neutron RBE with a biologically motivated model.
    Heidenreich WF; Carnes BA; Paretzke HG
    Radiat Res; 2006 Nov; 166(5):794-801. PubMed ID: 17067205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of neutrons in Hiroshima. Implications for the risk estimates.
    Kellerer AM
    C R Acad Sci III; 1999; 322(2-3):229-37. PubMed ID: 10196677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies of the mortality of A-bomb survivors. 9. Mortality, 1950-1985: Part 1. Comparison of risk coefficients for site-specific cancer mortality based on the DS86 and T65DR shielded kerma and organ doses.
    Shimizu Y; Kato H; Schull WJ; Preston DL; Fujita S; Pierce DA
    Radiat Res; 1989 Jun; 118(3):502-24. PubMed ID: 2727272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Choice of model and uncertainties of the gamma-ray and neutron dosimetry in relation to the chromosome aberrations data in Hiroshima and Nagasaki.
    Rühm W; Walsh L; Chomentowski M
    Radiat Environ Biophys; 2003 Jul; 42(2):119-28. PubMed ID: 12844221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flexible dose-response models for Japanese atomic bomb survivor data: Bayesian estimation and prediction of cancer risk.
    Bennett J; Little MP; Richardson S
    Radiat Environ Biophys; 2004 Dec; 43(4):233-45. PubMed ID: 15565453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective dose of A-bomb radiation in Hiroshima and Nagasaki as assessed by chromosomal effectiveness of spectrum energy photons and neutrons.
    Sasaki MS; Endo S; Ejima Y; Saito I; Okamura K; Oka Y; Hoshi M
    Radiat Environ Biophys; 2006 Jul; 45(2):79-91. PubMed ID: 16807767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutron relative biological effectiveness in Hiroshima and Nagasaki atomic bomb survivors: a critical review.
    Sasaki MS; Endo S; Hoshi M; Nomura T
    J Radiat Res; 2016 Nov; 57(6):583-595. PubMed ID: 27614201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.